Medicare Claims Processing Manual
Chapter 39 – Opioid Treatment Programs (OTPs)

Table of Contents
(Rev. 10665, 03-16-2)

Transmittals for Chapter 39

10 - General

20 - Statutory authority for OTPs billing Medicare

30 - Bundled payments for Opioid Use Disorder (OUD) treatment services
   30.1 - Duration of bundle
   30.2 - Requirements for an Episode
   30.3 - Non-drug episode of care
   30.4 - New drugs
   30.5 - Site of service (telecommunications)
   30.6 - Coding
      30.6.1 - Adjustments to Bundled Payment Rate
   30.7 - Cost Sharing
   30.8 - Locality Adjustments
   30.9 - Annual Updates

40 - Practitioner Claims submission – A/B MAC (B)
   40.1 - Place of Service
   40.2 - Date of Service
   40.3 - Prescribing Individuals

50 – Institutional Opioid Treatment Program (OTP) Services – A/B MAC (A)
   50.1 Special Opioid Treatment Program Billing Requirements for Hospitals, Critical Access Hospitals, and Free-Standing Opioid Treatment Program Facilities
10 - General  
(Rev. 4524: Issued; 02-14-20: Effective; 01-01-20: Implementation: 03-16-20)

This chapter provides claims processing instructions for Opioid Treatment Programs (OTPs).

The Medicare Benefit Policy Manual, Chapter 17, provides coverage policy for OTPs.

20 - Statutory authority for OTPs billing Medicare  
(Rev. 4524: Issued; 02-14-20: Effective; 01-01-20: Implementation: 03-16-20)

Section 2005 of the SUPPORT Act amended section 1861 of the Act by adding a new subsection (jjj)(2) to define an OTP as an entity meeting the definition of OTP in 42 CFR 8.2 or any successor regulation (that is, a program or practitioner engaged in opioid treatment of individuals with an opioid agonist treatment medication registered under 21 U.S.C. 823(g)(1)), that meets the additional requirements set forth in subparagraphs (A) through (D) of section 1861(jjj)(2) of the Act. Specifically that the OTP: is enrolled under section 1866(j) of the Act; has in effect a certification by the Substance Abuse and Mental Health Services Administration (SAMHSA) for such a program; is accredited by an accrediting body approved by SAMHSA; and meets such additional conditions as the Secretary may find necessary to ensure the health and safety of individuals being furnished services under such program and the effective and efficient furnishing of such services.

We defined “opioid treatment program” at § 410.67(b) as an entity that is an OTP as defined in § 8.2 (or any successor regulation) that meets the applicable requirements for an OTP. For an OTP to participate and receive payment under the Medicare program, the OTP must be enrolled under section 1866(j) of the Act, have in effect a certification by SAMHSA for such a program, and be accredited by an accrediting body approved by SAMHSA.

30 - Bundled payments for Opioid Use Disorder (OUD) treatment services  
(Rev. 4524: Issued; 02-14-20: Effective; 01-01-20: Implementation: 03-16-20)

The bundled payment rates are calculated by combining the drug component and the non-drug components.

30.1 - Duration of bundle  
(Rev. 4524: Issued; 02-14-20: Effective; 01-01-20: Implementation: 03-16-20)

An episode of care is defined at § 410.67(b) as a 1-week (contiguous 7-day) period.

There is no maximum number of weeks for a course of treatment for OUD.

30.2 - Requirements for an Episode  
(Rev. 4524: Issued; 02-14-20: Effective; 01-01-20: Implementation: 03-16-20)

In recognition that there is a range of service intensity depending on the severity of a patient’s OUD and stage of treatment, a “full weekly bundle” may consist of a very different frequency of services for a patient in the initial phase of treatment compared to a patient in the maintenance phase of treatment, or based on other factors such as pregnancy or relapse.

The threshold to bill the weekly episode is the delivery of at least one service in the weekly bundle (from either the drug or non-drug component) to the patient during the week that corresponds to the episode of care. If no drug was provided to the patient during that episode, the OTP must bill the G-code describing the weekly bundle not including the drug (HCPCS code 2074) and the threshold to bill would be at least one service in the non-drug component. If a drug was provided with or without additional non-drug component
services, the appropriate G-code describing the weekly bundle that includes the drug furnished may be billed.

30.3 - Non-drug episode of care
(Rev. 4524: Issued; 02-14-20: Effective; 01-01-20: Implementation: 03-16-20)

HCPCS code G2074 describes a non-drug episode of care. This provides a mechanism for OTPs to bill for non-drug services, including substance use counseling, individual and group therapy, and toxicology testing, that are rendered during weeks when a medication is not administered, for example, in cases where a patient is being treated with injectable buprenorphine or naltrexone on a monthly basis or has a buprenorphine implant.

30.4 - New drugs
(Rev. 4524: Issued; 02-14-20: Effective; 01-01-20: Implementation: 03-16-20)

We anticipate that there may be new Food and Drug Administration (FDA)-approved opioid agonist and antagonist treatment medications to treat OUD in the future.

OTPs may bill for an episode of care using the medication not otherwise specified (NOS) code (HCPCS code G2075) in the scenario where an OTP furnishes MAT using a new FDA-approved opioid agonist or antagonist medication for OUD treatment that is not specified in one of our existing codes. In such cases, the typical or average maintenance dose would be used to determine the drug cost for the new bundle, which contractors would then add to the non-drug component payment amount that corresponds with the relevant payment for drug administration (oral, injectable, or implantable) to determine the total bundled payment for the episode of care. Pricing for the drug component should be determined based on the relevant pricing methodology as described in the CY 2020 Physician Fee Schedule final rule or through invoice pricing in the event the information necessary to apply the relevant pricing methodology is not available.

30.5 - Site of service (telecommunications)
(Rev. 10665: Issued; 03-16-21: Effective; 01-01-21: Implementation: 04-15-21)

OTPs can use two-way interactive audio-video communication technology, as clinically appropriate, to furnish the substance use counseling and individual and group therapy services included in the bundled payment, as well as the add-on code for additional counseling and therapy. Additionally, beginning January 1, 2021, OTPs can use two-way interactive audio-video communication technology, as clinically appropriate, to furnish the periodic assessment add-on code. During the Public Health Emergency (PHE) for the COVID-19 pandemic, the therapy and counseling portions of the weekly bundles of services furnished by OTPs, as well as any additional counseling or therapy payable under the add-on code for additional counseling or therapy, may be furnished using audio-only telephone calls rather than via two-way interactive audio-video communication technology during the PHE for the COVID-19 pandemic if beneficiaries do not have access to two-way audio/video communications technology, provided all other applicable requirements are met.

Additionally, during the PHE, as defined in 42 CFR 400.200, periodic assessments may be furnished via two-way interactive audio-video communication technology, as clinically appropriate, and in compliance with all applicable requirements, and in cases where a beneficiary does not have access to two-way audio-video communications technology, periodic assessments can be furnished using audio-only telephone calls during the PHE if all other applicable requirements are met. As OTP services are not PFS services, no originating site facility fee (HCPCS code Q3014) applies to OUD treatment services, and OTPs are not authorized to bill for the originating site facility fee. Additionally, the payment for the substance use counseling and individual and group therapy are included in the bundled payment rates made to OTPs; therefore, the practitioner furnishing the service remotely should not bill separately for the service.
30.6 – Coding
(Rev. 10665: Issued; 03-16-21: Effective; 01-01-21: Implementation: 04-15-21)

The codes describing bundled payments made to OTPs are HCPCS codes G2067-G2075. There are add-on codes described by HCPCS codes G2076-G2080 and HCPCS codes G2215 and G2216. Only an entity enrolled with Medicare as an OTP can bill these codes. Additionally, OTPs are limited to billing only these codes describing bundled payments, and may not bill for other codes, such as those paid under the PFS.

The coding structure for OUD treatment services varies by the medication administered. There are G codes for weekly bundles describing treatment with methadone, oral buprenorphine, injectable buprenorphine, buprenorphine implants (insertion, removal, and insertion/removal), extended-release injectable naltrexone, a non-drug bundle, and one for a medication not otherwise specified (see full list of codes below).

The code describing the bundled payment for an episode of care with a medication not otherwise specified (HCPCS code G2075) should be used when the OTP furnishes MAT with a new opioid agonist or antagonist treatment medication approved by the FDA under section 505 of the FFDCA for the treatment of OUD. OTPs may use this code until CMS has the opportunity to propose and finalize a new G code to describe the bundled payment for treatment using that drug and price it accordingly in the next rulemaking cycle. HCPCS code G2075 should not be used when the drug being administered is not a new opioid agonist or antagonist treatment medication approved by the FDA under section 505 of the FFDCA for the treatment of OUD, and therefore, for which Medicare would not have the authority to make payment since section 1861(jjj)(1)(A) of the Act requires that the medication must be an opioid agonist or antagonist treatment medication approved by the FDA under section 505 of the FFDCA for the treatment of OUD.

The code describing the bundled payment for an episode of care with a medication not otherwise specified (HCPCS code G2075) should be used when the OTP furnishes MAT with a new opioid agonist or antagonist treatment medication approved by the FDA under section 505 of the FFDCA for the treatment of OUD. OTPs may use this code until CMS has the opportunity to propose and finalize a new G code to describe the bundled payment for treatment using that drug and price it accordingly in the next rulemaking cycle. HCPCS code G2075 should not be used when the drug being administered is not a new opioid agonist or antagonist treatment medication approved by the FDA under section 505 of the FFDCA for the treatment of OUD, and therefore, for which Medicare would not have the authority to make payment since section 1861(jjj)(1)(A) of the Act requires that the medication must be an opioid agonist or antagonist treatment medication approved by the FDA under section 505 of the FFDCA for the treatment of OUD.

HCPCS code G2074, which describes a non-drug bundle, can be billed for services furnished during an episode of care when a medication is not administered, but other services in the bundle are furnished. For example, when a patient receives a buprenorphine injection on a monthly basis, the OTP will only require payment for the medication during the first week of the month when the injection is given, and therefore, would bill the code describing the bundle that includes injectable buprenorphine during the first week of the month and would bill the code describing the non-drug bundle for the remaining weeks in that month for services such as substance use counseling, individual and group therapy, and toxicology testing.

NOTE: Some of the bundled payment codes describe a drug that is typically only administered once per month, such as the injectable drugs, or once in a 6-month period, in the case of the buprenorphine implants. In those cases, the code describing the bundled payment that includes the cost of the drug would be billed during the week that the drug is administered, and if at least one service is furnished in a subsequent week, the non-drug bundle would be billed. For example, in the case of a patient receiving injectable buprenorphine, we would expect that HCPCS code G2069 would be billed for the week during which the injection was administered and that HCPCS code G2074, which describes a bundle not including the drug, would be billed during any subsequent weeks that at least one non-drug service is furnished until the injection is administered again, at which time HCPCS code G2069 would be billed again for that week. We note that as HCPCS codes G2067 – G2075 cover episodes of care of 7 contiguous days, we will not permit an OTP to bill any of these codes for the same beneficiary more than once per 7 contiguous day period. Additionally, consistent with FDA labelling, we do not generally expect the codes describing bundled payments including the injectable drugs (HCPCS codes G2069 and G2073) to be furnished more than once every 4 weeks. Similarly, consistent with FDA labelling, we do not generally expect the codes describing bundled payments including insertion of the buprenorphine implants (HCPCS codes G2070 and G2072) to be furnished more than once every 6 months.

We understand there are limited clinical scenarios when a beneficiary may be appropriately furnished OUD treatment services at more than one OTP within a 7 contiguous day period, such as for guest dosing or when a beneficiary transfers care between OTPs. In these limited circumstances, each of the involved OTPs may bill the appropriate HCPCS codes that reflect the services furnished to the beneficiary. We expect that both OTPs involved would provide sufficient documentation in the patient’s medical record to reflect the clinical situation and services provided. Additionally, in instances in which a patient is switching from one drug to
another, the OTP should only bill for one code describing a weekly bundled payment for that week and should determine which code to bill based on which drug was furnished for the majority of the week.

30.6.1 - Adjustments to Bundled Payment Rate

(Rev. 10665: Issued; 03-16-21: Effective; 01-01-21: Implementation: 04-15-21)

There are add-on codes for intake activities, periodic assessments, take-home supplies of methadone, take-home supplies of oral buprenorphine, additional counseling or therapy services furnished, and for take-home supplies of naloxone.

We note that the add-on code describing intake activities (HCPCS code G2076) should only be billed for new patients (that is, patients starting treatment at the OTP).

There are two add-on codes that describe take-home doses of medication, one for take-home supplies of methadone (HCPCS code G2078), which describes up to 7 additional days of medication, and can be billed along with the respective weekly bundled payment in units of up to 3 (for a total of up to a one month supply), and one for take-home supplies of oral buprenorphine (HCPCS code G2079), which also describes up to 7 additional days of medication and can be billed along with the base bundle in units of up to 3 (for a total of up to a 1 month supply). SAMHSA allows a maximum take-home supply of one month of medication; therefore, we do not expect the add-on codes describing take-home doses of methadone and oral buprenorphine to be billed any more than 3 times in one month (in addition to the weekly bundled payment). The add-on code for take-home doses of methadone can only be used with the methadone weekly episode of care code (HCPCS code G2067). Similarly, the add-on code for take-home doses of oral buprenorphine can only be used with the oral buprenorphine weekly episode of care code (HCPCS code G2068).

HCPCS code G2080 may be billed when counseling or therapy services are furnished that substantially exceed the amount specified in the patient’s individualized treatment plan. OTPs are required to document the medical necessity for these services in the patient’s medical record.

The codes and long descriptors for the OTP bundled services and add-on services are:

- HCPCS code G2067: Medication assisted treatment, methadone; weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing, if performed (provision of the services by a Medicare-enrolled Opioid Treatment Program).

- HCPCS code G2068: Medication assisted treatment, buprenorphine (oral); weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled Opioid Treatment Program).

- HCPCS code G2069: Medication assisted treatment, buprenorphine (injectable); weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled Opioid Treatment Program).

- HCPCS code G2070: Medication assisted treatment, buprenorphine (implant insertion); weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled Opioid Treatment Program).

- HCPCS code G2071: Medication assisted treatment, buprenorphine (implant removal); weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled Opioid Treatment Program).

- HCPCS code G2072: Medication assisted treatment, buprenorphine (implant insertion and removal); weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled Opioid Treatment Program).
therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled Opioid Treatment Program).

- **HCPCS code G2073**: Medication assisted treatment, naltrexone; weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled Opioid Treatment Program).

- **HCPCS code G2074**: Medication assisted treatment, weekly bundle not including the drug, including substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled Opioid Treatment Program).

- **HCPCS code G2075**: Medication assisted treatment, medication not otherwise specified; weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing, if performed (provision of the services by a Medicare-enrolled Opioid Treatment Program).

- **HCPCS code G2076**: Intake activities, including initial medical examination that is a complete, fully documented physical evaluation and initial assessment conducted by a program physician or a primary care physician, or an authorized healthcare professional under the supervision of a program physician or qualified personnel that includes preparation of a treatment plan that includes the patient’s short-term goals and the tasks the patient must perform to complete the short-term goals; the patient’s requirements for education, vocational rehabilitation, and employment; and the medical, psycho- social, economic, legal, or other supportive services that a patient needs, conducted by qualified personnel (provision of the services by a Medicare-enrolled Opioid Treatment Program); List separately in addition to code for primary procedure.

- **HCPCS code G2077**: Periodic assessment; assessing periodically by qualified personnel to determine the most appropriate combination of services and treatment (provision of the services by a Medicare-enrolled Opioid Treatment Program); List separately in addition to code for primary procedure.

- **HCPCS code G2078**: Take-home supply of methadone; up to 7 additional day supply (provision of the services by a Medicare-enrolled Opioid Treatment Program); List separately in addition to code for primary procedure.

- **HCPCS code G2079**: Take-home supply of buprenorphine (oral); up to 7 additional day supply (provision of the services by a Medicare-enrolled Opioid Treatment Program); List separately in addition to code for primary procedure.

- **HCPCS code G2080**: Each additional 30 minutes of counseling or group or individual therapy in a week of medication assisted treatment, (provision of the services by a Medicare-enrolled Opioid Treatment Program); List separately in addition to code for primary procedure.

- **HCPCS code G2215**: Take-home supply of nasal naloxone (provision of the services by a Medicare-enrolled Opioid Treatment Program); List separately in addition to code for primary procedure.

- **HCPCS code G2216**: Take-home supply of injectable naloxone (provision of the services by a Medicare-enrolled Opioid Treatment Program); List separately in addition to code for primary procedure.

### 30.7 - Cost Sharing


There is zero beneficiary copayment for the codes billed by OTPs. However, the Part B deductible does apply, as mandated for all Part B services by section 1833(b) of the Act.
30.8 - Locality Adjustments  
(Rev. 10665: Issued; 03-16-21: Effective; 01-01-21: Implementation: 04-15-21)

The payment amounts for the non-drug component of the bundled payment for an episode of care, and the adjustments for counseling or therapy, intake activities, periodic assessments, and take-home supplies of naloxone (HCPCS codes G2067-G2077, G2080, G2215, and G2216) will be geographically adjusted using the Geographic Adjustment Factor.

30.9 - Annual Updates  
(Rev. 4524: Issued; 02-14-20: Effective; 01-01-20: Implementation: 03-16-20)

The payment amounts for the non-drug component of the bundled payment for an episode of care, and the adjustments for counseling or therapy, intake activities and periodic assessments (HCPCS codes G2067-G2077, and G2080) will be updated annually using the Medicare Economic Index.

40 - Practitioner Claims submission – A/B MAC (B)  
(Rev. 10665: Issued; 03-16-21: Effective; 01-01-21: Implementation: 04-15-21)

Beginning January 1, 2020, claims for OTP services are submitted using the 837P transaction to transmit health care claims electronically, or using the CMS-1500 (the paper version of the 837P). Beginning January 1, 2021, OTPs may apply on the Medicare Enrollment Application for Institutional Providers (CMS-855A) or through the Internet-based Provider Enrollment, Chain and Ownership System (PECOS) (837I) when they enroll in the Medicare Program. These providers will submit claims using the CMS-1450.

HCPCS codes G2067-G2075 cover episodes of care of 7 continuous days and cannot be billed for the same patient more than once per 7 continuous day period.

HCPCS codes G2076-G2080 are add-on codes that are billed in addition to one of the base bundle codes described by HCPCS codes G2067-G2075.

Consistent with FDA labeling, HCPCS codes G2069 and G2073 should not be used more than once every 4 weeks and HCPCS codes G2070 and G2072 should not be used more than once every 6 months. HCPCS codes G2078 and G2079 may be billed in multiple units, up to 3 in one month (in addition to the base bundle code).

HCPCS codes G2215 and G2216 are limited to being billed once every 30 days, however, exceptions to this limit are allowed in the case where the beneficiary overdoses and uses the initial supply of naloxone dispensed by the OTP to the extent that it is medically reasonable and necessary to furnish additional naloxone. If an additional supply of naloxone is needed within 30 days of the original supply being provided, OTPs must document in the medical record the reason for the exception. HCPCS code G2216 (injectable naloxone) is contractor-priced for CY 2021.

Patients may be appropriately given OUD services at more than one OTP within a 7 day period in certain limited clinical situations, such as for guest dosing or when a patient transfers care between OTPs. Each of the involved OTPs may bill the appropriate HCPCS codes for the services provided to the patient, but both OTPs must maintain sufficient medical record documentation to reflect the clinical situation and services provided.

In instances in which a patient is switching from one drug to another, the OTP should only bill for one code describing a weekly bundled payment for that week and should determine which code to bill based on which drug was furnished for the majority of the week.

40.1 - Place of Service
Claims for OTP services should use Place of Service code 58 (Non-residential Opioid Treatment Facility – a location that provides treatment for OUD on an ambulatory basis. Services include methadone and other forms of MAT).

**40.2 - Date of Service**  
(Rev. 4524: Issued; 02-14-20: Effective; 01-01-20: Implementation: 03-16-20)

For the codes that describe a weekly bundle (HCPCS codes G2067-G2075), one week is defined as 7 contiguous days. OTPs may choose to apply a standard billing cycle by setting a particular day of the week to begin all episodes of care. In this case, the date of service would be the first day of the OTP’s billing cycle. If a beneficiary starts treatment at the OTP on a day that is in the middle of the OTP’s standard weekly billing cycle, the OTP may still bill the applicable code for that episode of care provided that the threshold to bill for the code has been met.

Alternatively, OTPs may choose to adopt weekly billing cycles that vary across patients. Under this approach, the initial date of service will depend upon the day of the week when the patient was first admitted to the program or when Medicare billing began. Therefore, under this approach of adopting weekly billing cycles that vary across patients, when a patient is beginning treatment or re-starting treatment after a break in treatment, the date of service would reflect the first day the patient was seen and the date of service for subsequent consecutive episodes of care would be the first day after the previous 7-day period ends.

For the codes describing add-on services (HCPCS codes G2076-G2080), the date of service should reflect the date that service was furnished; however, if the OTP has chosen to apply a standard weekly billing cycle, the date of service for codes describing add-on services may be the same as the first day in the weekly billing cycle.

**40.3 - Prescribing Individuals**  
(Rev. 4524: Issued; 02-14-20: Effective; 01-01-20: Implementation: 03-16-20)

OTPs should list the prescribing or medication ordering physician’s or other eligible professional’s National Provider Identifier in Field 17 (the ordering/referring/other field) of the Form CMS–1500 (Health Insurance Claim Form; 0938–1197) or the digital equivalent thereof.

**50 – Institutional Opioid Treatment Program (OTP) Services – A/B MAC (A)**  
(Rev. 10521; Issued: 12-16-20; Effective: 01-01-21; Implementation: 01-04-21)

Medicare Part B coverage is available for outpatient Opioid Treatment Program services provided by hospitals, CAHs, and Free-Standing Opioid Treatment Program facilities.

**50.1 – Special Opioid Treatment Program Billing Requirements for Hospitals, Critical Access Hospitals, and Free-Standing Opioid Treatment Program Facilities**  
(Rev. 10521; Issued: 12-16-20; Effective: 01-01-21; Implementation: 01-04-21)

Medicare Part B coverage is available for hospital outpatient Opioid Treatment Program services.

**A. Billing Requirement**
Section 1861(s)(2)(HH)(jjj) of the Act requires that opioid use disorder treatment services would include the Food and Drug Administration (FDA)-approved opioid agonist and antagonist treatment medications, the
dispensing and administration of such medications (if applicable), substance use disorder counseling, individual
and group therapy, toxicology testing, and other items and services that the Secretary determines are appropriate.
Section 1861(s)(2)(HH)(jjj) defines OTPs as those that enroll in Medicare and are certified by the Substance
Abuse and Mental Health Services Administration (SAMHSA), accredited by a SAMHSA-approved entity, and
meet additional conditions as the Secretary finds necessary to ensure the health and safety of individuals being
furnished services under these programs and the effective and efficient furnishing of such services.

Hospitals and CAHs report condition code 89 in FLs 18-28 (or electronic equivalent) to indicate the claim is for
Opioid Treatment Program services. They must also report a revenue code and the charge for each individual
covered service furnished. In addition, hospital outpatient departments are required to report HCPCS codes.
CAHs are not required to report HCPCS code for this benefit.

Under component billing, hospitals are required to report a revenue code and the charge for each individual
covered service furnished under an opioid treatment program. In addition, hospital outpatient departments are
required to report HCPCS codes. Component billing assures that only those opioid treatment program services
covered under §1861(s)(2)(HH)(jjj) of the Act are paid by the Medicare program.

All hospitals are required to report condition code “89” in FLs 18-28 to indicate the claim is for opioid treatment
program services. Hospitals use bill type 013X and CAHs use bill type 085X. The following special procedures
apply:

Bills must contain an acceptable revenue code. They are as follows:

<table>
<thead>
<tr>
<th>Revenue Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>0636</td>
<td>Drugs Requiring Detailed Coding</td>
</tr>
<tr>
<td>0900</td>
<td>Behavioral Health Treatment/Services</td>
</tr>
<tr>
<td>0914</td>
<td>Individual Therapy</td>
</tr>
<tr>
<td>0915</td>
<td>Group Therapy</td>
</tr>
<tr>
<td>0916</td>
<td>Family Therapy</td>
</tr>
<tr>
<td>0918</td>
<td>Behavioral Health/Testing</td>
</tr>
<tr>
<td>0919</td>
<td>Other Behavioral Health Treatments</td>
</tr>
<tr>
<td>0940</td>
<td>General Classification</td>
</tr>
<tr>
<td>0944</td>
<td>Drug Rehabilitation</td>
</tr>
<tr>
<td>0949</td>
<td>Other Therapeutic Service</td>
</tr>
<tr>
<td>0953</td>
<td>Chemical Dependency (Drug and Alcohol)</td>
</tr>
</tbody>
</table>

Hospitals other than CAHs are also required to report appropriate HCPCS codes.

Edit to assure that HCPCS are present when the above revenue codes are billed and that they are valid HCPCS
codes. Do not edit for the matching of revenue code to HCPCS.

NOTE: Information regarding the Form CMS-1450 form locators that correspond with these fields is found in
Chapter 25 of this manual. See the ASC X12 837 Institutional Claim implementation guide for related guidelines
for the electronic claim.

B. Reporting of Service Units

Hospitals and Free-Standing facilities report the number of times the service or procedure, as defined by the
HCPCS code, was performed.

NOTE: Service units are not required to be reported for drugs and biologicals (Revenue Code 250).

C. Line Item Date of Service Reporting

Hospitals other than CAHs are required to report line item dates of service per revenue code line for opioid
treatment program claims. This means each service (revenue code) provided must be repeated on a separate line
item along with the specific date the service was provided for every occurrence. Line item dates of service are reported in FL 45 “Service Date” (MMDDYY).

D. Special Requirements for Free-Standing Opioid Treatment Program Facilities

Section 1833 (s)(2)(HH)(jjj)) of the Act recognizes Free-Standing Opioid Treatment Program Facilities as “providers of services” but only for furnishing Opioid Treatment Program services. Applicable provider ranges are xx9900-xx9999 billed on a claim with a type of bill 087x. Other billing requirements (except condition code “89” reporting) mentioned above for hospitals apply.

E. Payment

Section 1861 (s)(2)(HH)(jjj)) of the Act provides the statutory authority governing payment for opioid treatment program services provided by a hospital or free-standing facility. A/B MAC(s) (A) make payment on a fee schedule basis (see 30.8). CAH’s are paid at reasonable cost basis. The Part B deductible applies. There is no PC/TC split for OTP billing. Only one (1) provider may bill for the services of the opioid treatment program, either the facility or the practitioner, but not both.

F. Data for CWF and PS&R

Include revenue codes, HCPCS/CPT codes, units, and covered charges in the financial data section (fields 65a - 65j), as appropriate. Report the billed charges in field 65h, "Charges," of the CWF record.

Include in the financial data portion of the PS&R UNIBILL, revenue codes, HCPCS/CPT codes, units, and charges, as appropriate.

G. Medical Review

The A/B MACs (A) follow medical review guidelines in Pub. 100-08, Medicare Program Integrity Manual.
## Transmittals Issued for this Chapter

<table>
<thead>
<tr>
<th>Rev #</th>
<th>Issue Date</th>
<th>Subject</th>
<th>Impl Date</th>
<th>CR#</th>
</tr>
</thead>
<tbody>
<tr>
<td>R10665CP</td>
<td>03/16/2021</td>
<td>Updates to Medicare Benefit Policy Manual and Medicare Claims Processing Manual for Opioid Treatment Programs (Manual Updates Only)</td>
<td>04/15/2021</td>
<td>12161</td>
</tr>
<tr>
<td>R10521CP</td>
<td>12/16/2020</td>
<td>New Medicare National Uniform Billing Committee (NUBC) Type of Bill (TOB), Condition Code and implementing Billing Codes for Opioid Treatment Programs</td>
<td>01/04/2021</td>
<td>11856</td>
</tr>
<tr>
<td></td>
<td>08/06/2020</td>
<td>New Medicare National Uniform Billing Committee (NUBC) Type of Bill (TOB), Condition Code and implementing Billing Codes for Opioid Treatment Programs – Rescinded and replaced by transmittal 10521</td>
<td>01/04/2021</td>
<td>11856</td>
</tr>
<tr>
<td></td>
<td>02/14/2020</td>
<td>Update to Medicare Benefit Policy Manual and Medicare Claims Processing Manual Adding New Chapters for Opioid Treatment Programs (Manual Updates Only)</td>
<td>03/16/2020</td>
<td>11620</td>
</tr>
</tbody>
</table>

[Back to Top of Chapter]